Running Head: Assays to discover new anti-HCMV compounds 2 Human cytomegalovirus (HCMV) infection is responsible for severe, often even fatal, diseases in immunocompromised subjects and also represents the major cause of viral-associated congenital malformations in newborn children. The few drugs licensed for anti-HCMV therapy suffer from many drawbacks and none of them have been approved for the treatment of congenital infections.
Introduction
Human cytomegalovirus (HCMV) infection is associated with severe morbidity and mortality in immunocompromised individuals, such as transplant recipients and AIDS patients, and is also the most frequent cause of viral-associated congenital defects in newborn children. The few drugs currently licensed for anti-HCMV therapy, most of which target the catalytic activity of the viral DNA polymerase, suffer from many drawbacks, including low potency, poor bioavailability, and long-term toxicity; furthermore, none of these drugs have been approved for the treatment of congenital infections. Additionally, due to the fact that most of the current anti-HCMV drugs share the same mechanism of action, the emergence of drug-resistant viral strains is becoming an increasing problem for disease management. Thus, there is a strong need for novel anti-HCMV drugs that are more potent, less toxic, and possibly act by a mechanism of action different from that of the currently available drugs.
The viral DNA polymerase represents a major target for anti-virals (1) , and new compounds that act by disrupting the interactions between the polymerase subunits rather than inhibiting the enzyme catalytic activity have been recently discovered, thus demonstrating the feasibility of alternative antiviral strategies (2) . In addition, the earliest events of the virus replication cycle, in particular the functions of the immediate-early 2 (IE2) protein, represent attractive targets for the development of novel antiviral compounds (3) . In fact, the multifunctional IE2 protein is crucial for regulation of viral early (E) gene expression and there is compelling evidence that it plays a direct role in the pathogenesis of HCMV infection by inducing a broad dysregulation of host gene expression.
This leads to changes in host cell physiology and contributes to HCMV-induced cell cycle alterations, immunomodulation, and proinflammatory responses. Thus, molecules that inhibit IE2-dependent activities may be effective in blocking the virus-induced pathological phenomena at an early stage of infection. Moreover, inhibitors of IE2 could be of particular importance for the treatment of patients who do not respond to currently available inhibitors of viral DNA replication.
In this chapter we will describe novel approaches to develop new compounds against HCMV.
First, we will focus on two kinds of in vitro assays to identify compounds able to inhibit protein-protein interactions essential for HCMV replication. As an example, we will describe two different methods for identifying inhibitors of the interactions occurring between the two subunits of HCMV DNA polymerase, i.e., UL54 and UL44, which are essential for viral genome replication. However, these approaches can be applied to virtually every molecular interaction for which the interacting domains have been identified.
The first assay is based on measurement of fluorescence polarization (FP), which is a simple and rapid method to study molecular interactions and their inhibition. The basic principle of an FP-based assay is that a peptide or another molecule of small size (e.g., an oligodeoxynucleotide) labelled with a fluorophore rotates rapidly when free in solution. When the conjugated fluorophore is excited with plane polarized light, the emitted fluorescence is depolarized (i.e., in a plane different from the excitation light). When the rotation is slowed down due to an interaction with a molecule of greater size (e.g., a protein or another kind of ligand), the fluorophore tumbles slowly with respect to fluorescence life-time and hence the emitted light remains polarized. The presence of an inhibitor of the molecular interaction between the small, labelled molecule and the large ligand causes a depolarization that can be quantitatively detected by using an FP reader. The advantages of FP assays are that the detection limits are in the sub-nanomolar range, it is performed in solution, it does not require immobilization or washing steps, it is very rapid, and it permits quantitative measurements. Altogether, these features render an FP-based assay suitable for the screening of a large number of compounds, and thus it is very useful for high-throughput screenings (HTS). In addition, FP-based assays can be used for the identification of inhibitors not only of protein-protein interactions, but also of protein-nucleic acid interactions (e.g., binding of transcription factors to specific promoters or other viral DNA or RNA sequences) (4, 5) . Fig. 1 illustrates the principles of an FP-based assay to discover inhibitors of proteinprotein interactions.
The second approach is based on the enzyme-linked immunosorbent assay (ELISA) and is recommended for the screening of a restricted number of compounds, for example for testing compounds identified from in silico screenings of small-molecule structures or for the validation of compounds discovered by HTS. However, this assay can be an alternative to the FP-based assay for those who do not possess a FP reader.
Finally, we will describe a cell-based assay designed to discover inhibitors of IE2 protein activities. This assay is based on new reporter cell lines derived from a stably transfected human cell line permissive to HCMV replication, in which the expression of the enhanced green fluorescent protein (EGFP) reporter gene is driven by the HCMV E UL54 or UL112/113 gene promoters that can betransactivated by the IE2 protein alone (6, 7) . The EGFP-expressing cell lines show a specific and inducible dose-and time-dependent EGFP response to either HCMV infection or constitutive IE2 expression that can be visually assessed by fluorescence microscopy or evaluated by automated fluorometry (8) . The reliability of these reporter cell lines for assessing virus-inhibitory effects in concentration-and time-dependent fashions after HCMV infection or IE2 transfection has been demonstrated by treatment with fomivirsen, an antisense oligodeoxynucleotide designed to block IE2 expression (8, 9) , and with WC5, a novel 6-aminoquinolone endowed with potent inhibitory activity for HCMV replication (10) . Thus, these EGFP-based cell lines can be exploited as a tool to screen antiviral compounds that specifically target IE2 expression and/or function. 2. G418 stock solution (50 mg/ml).
3. Growth medium for 2F7 and 1B4 cells: Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), and 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin sulphate, 750 µg/ml G418.
PBS.
5. 100 g/ml trypsin and 2 mM EDTA in PBS.
Infection of the reporter cells lines 2F7 and 1B4
1. HCMV stocks: HCMV laboratory strainAD169 (ATCC, #VR-538) is propagated and titered in lowpassage human embryonic lung fibroblasts (HELF) by standard protocols. HCMV clinical isolates are propagated in low-passage human umbilical vein endothelial cells (HUVEC) and titered by the indirect immunoperoxidase staining procedure on HELFs using a MAb reactive to the HCMV IE1 and IE2
proteins (see Note 12).
2. Maintenance medium for HCMV-infected 2F7 and 1B4 cells: DMEM supplemented with 5% FBS and 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin sulfate.
Quantification of EGFP expression in HCMV-infected 2F7 and 1B4 cells by fluorescence microscopy
1. Glass coverslips in 24-well plates.
PBS.
3. Fixing solution: 4% paraformaldehyde in PBS.
4. Mounting medium (e.g., Vectashield). 3. Add potential small molecule inhibitors to the 96 or 384 well plates at a final concentration of 12.5 µg/ml, or the same volume of compound vehicle (e.g., DMSO; see Note 7), to exclude potential inhibitory effects due to compound vehicle. It is preferable to test each potential inhibitor in duplicate.
Quantification of EGFP expression HCMV-infected

Methods
Fluorescence polarization (FP
As controls, include wells with the UL54-derived peptide and GST-UL44ΔC290 protein mixture with no compound and also include wells with the UL54-derived peptide only (see Note 5). In addition, as a positive control for inhibition of the interaction between UL44 and UL54, add unlabelled UL54-derived peptide at a final concentration of 20 µM in duplicate wells.
4. Incubate at room temperature (RT) for 15 min. 3. Block with 0.1 ml/well of 2% BSA in PBS at RT for 1 h.
4. Aspirate and wash as described in Step 2.
5. Add 0.5 µg/well of purified, baculovirus-expressed UL44 protein dissolved in PBS alone or mixed with test compounds (previously dissolved in DMSO) at the desired final concentration in duplicate wells (see Notes 7 and 8). As controls, include wells with the UL54 protein alone (i.e, do not add UL44 protein and inhibitors, but add the same volume of PBS; this is a control for antibody specificity), wells coated with the UL54 protein and incubated with UL44 protein mixed with the UL54-derived peptide (the UL54-derived peptide is a known inhibitor of UL54-UL44 interaction; thus, this is a positive control for inhibition), and wells coated with the UL54 protein and incubated with UL44 protein mixed with compound vehicle (e.g., DMSO; see Note 7). The latter control is to exclude inhibitory effects due to compound vehicle.
6. Incubate the plates at 37°C for 1 h to allow protein-protein interaction.
7. Aspirate and wash as described in Step 2.
8. Add 50 µl/well of YL1/2 MAb diluted 1:50 in PBS containing 2% FBS and incubate at 37°C for 1 h in the dark.
9. Aspirate and wash as described in Step 2.
10. Add 50 µl/well of HRP-conjugated anti-rat antibody diluted 1:500 in PBS with 2% FBS and incubate at RT for 1 h.
11. Aspirate and wash as described in Step 2.
12. Add 100 µl/well of ABTS solution (prepared as described in section 2, Materials) and incubate at RT for 15 min in dark (see Note 9). Block the reaction by adding 50 µl/well of 3 N NaOH (see Note 10).
13. Measure absorbance at 405 nm using an appropriate ELISA reader.
14. Typical results of an ELISA-based assay designed to search for inhibitors of the interaction between the two subunits, UL54 and UL44, of HCMV DNA polymerase are shown in Fig. 3. 
Cell-based assay
Cultivation of the reporter cells lines 2F7 and 1B4
1. For maintenance, 2F7 and 1B4 cells are routinely cultured in DMEM-10% FBS containing 750 µg/ml G418. Cells up to 60 th passage can be used for HCMV quantification and antiviral assays.
2. Cells are subcultured by trypsinization with a solution of 100 g/ml trypsin in PBS-2 mM EDTA solution to obtain new maintenance cultures using a split ratio of 1:3. It is recommended to subculture the cells prior to reaching confluence.
Infection of the reporter cells lines 2F7 and 1B4
1. Seed 2F7 and 1B4 cells in 24-or 96-well plates at a density of 70×10 3 or 10×10 3 cells/well, respectively.
2. After 24 h, remove the growth medium by aspiration, and immediately add a small volume of viral inoculum (0.25 ml for 24 well plate or 0.05 ml for 96 well plate) that is prepared by diluting viral stocks solutions in maintenance medium for HCMV-infected cells to obtain the appropriate multiplicity of infection (MOI). Plates should be gently rocked to achieve even distribution of the viral inoculum.
3. Incubate infected cells for 2 h at 37°C in a humidified incubator with 5% CO 2 to allow virus adsorption.
4. Remove viral inoculum by aspiration and add an appropriate volume of DMEM with 5% FBS to each well and incubate in a CO 2 incubator at 37° C. or HCMV clinical isolates as described in Subheading 3.3.2.
2. Prepare in advance the following solutions: precooled (on ice) PBS and fixing solution. 7. Evaluate the numbers of EGFP expressing cells in captured images using an image processing software package (e.g., Image J).
8. Fig. 4 shows a typical result of a fluorescent microscopy evaluation of EGFP expression in 2F7 and 1B4 cells infected with HCMV AD169 for 72 and 96 h (see Note 13). 6. Estimate the IE2-dependent EGFP expression at each drug concentration.
Quantification of EGFP expression in HCMV-
7. Determine the 50% inhibitory concentration (IC 50 ) values using dose response curves (see Note 15).
8. An example of the concentration-dependent inhibitory effect of the IE2-targeting antisense oligodeoxynucleotide fomivirsen on EGFP expression measured in HCMV AD169-infected 2F7 and 1B4 cells at 48 h.p.i., is shown in Fig. 5 (left panel) . In comparison, the same concentrations of fomivirsen were evaluated by a conventional plaque reduction assay in HELFs (Fig. 5, right panel) . 4. Samples can be either automatically dispensed using a 384-pin array or manually dispensed. When manually dispensed, a 96-well format is recommended in order to avoid variability among first and last samples.
5. If using an automated dispenser, 0.1 µl of each compound at 5 mg/ml is transferred to individual wells using a 384-pin array.
6. To avoid differences among the wells, the use of a multi-channel pipette is recommended.
7. Ensure that the final DMSO concentration in each well is not higher than 1% to avoid non-specific effects of DMSO.
8. Mix equal volume of UL44 and peptides, e.g. 60 µl of UL44 and 60 µl of peptide solution. Taken together, these studies indicate that the sensitivity of the EGFP-based fluorescence assay is similar to that of the plaque reduction assays in measuring the antiviral activity of fomivirsen (8) . 
